Logo image of TDOC

TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis

NYSE:TDOC - US87918A1051 - Common Stock

7.76 USD
+0.12 (+1.57%)
Last: 9/3/2025, 7:29:25 PM
7.7409 USD
-0.02 (-0.25%)
After Hours: 9/3/2025, 7:29:25 PM
Fundamental Rating

3

TDOC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. TDOC has a bad profitability rating. Also its financial health evaluation is rather negative. TDOC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year TDOC has reported negative net income.
TDOC had a positive operating cash flow in the past year.
In the past 5 years TDOC always reported negative net income.
TDOC had a positive operating cash flow in 4 of the past 5 years.
TDOC Yearly Net Income VS EBIT VS OCF VS FCFTDOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5B -10B

1.2 Ratios

TDOC has a better Return On Assets (-7.17%) than 71.43% of its industry peers.
TDOC's Return On Equity of -14.58% is fine compared to the rest of the industry. TDOC outperforms 65.71% of its industry peers.
Industry RankSector Rank
ROA -7.17%
ROE -14.58%
ROIC N/A
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
TDOC Yearly ROA, ROE, ROICTDOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

With a decent Gross Margin value of 70.26%, TDOC is doing good in the industry, outperforming 77.14% of the companies in the same industry.
In the last couple of years the Gross Margin of TDOC has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TDOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
TDOC Yearly Profit, Operating, Gross MarginsTDOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
TDOC has more shares outstanding than it did 1 year ago.
TDOC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TDOC has a worse debt to assets ratio.
TDOC Yearly Shares OutstandingTDOC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TDOC Yearly Total Debt VS Total AssetsTDOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

Based on the Altman-Z score of -6.41, we must say that TDOC is in the distress zone and has some risk of bankruptcy.
TDOC's Altman-Z score of -6.41 is on the low side compared to the rest of the industry. TDOC is outperformed by 88.57% of its industry peers.
The Debt to FCF ratio of TDOC is 6.57, which is on the high side as it means it would take TDOC, 6.57 years of fcf income to pay off all of its debts.
TDOC's Debt to FCF ratio of 6.57 is in line compared to the rest of the industry. TDOC outperforms 54.29% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that TDOC is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.70, TDOC is doing worse than 71.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 6.57
Altman-Z -6.41
ROIC/WACCN/A
WACC7.61%
TDOC Yearly LT Debt VS Equity VS FCFTDOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

TDOC has a Current Ratio of 2.67. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
TDOC has a Current ratio (2.67) which is comparable to the rest of the industry.
A Quick Ratio of 2.58 indicates that TDOC has no problem at all paying its short term obligations.
With a Quick ratio value of 2.58, TDOC perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.58
TDOC Yearly Current Assets VS Current LiabilitesTDOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

3

3. Growth

3.1 Past

TDOC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.75%.
Looking at the last year, TDOC shows a decrease in Revenue. The Revenue has decreased by -2.57% in the last year.
The Revenue has been growing by 35.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.14%
Revenue 1Y (TTM)-2.57%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-1.64%

3.2 Future

The Earnings Per Share is expected to grow by 6.70% on average over the next years.
The Revenue is expected to grow by 2.58% on average over the next years.
EPS Next Y8.25%
EPS Next 2Y16.58%
EPS Next 3Y11.86%
EPS Next 5Y6.7%
Revenue Next Year-1.83%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.37%
Revenue Next 5Y2.58%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TDOC Yearly Revenue VS EstimatesTDOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
TDOC Yearly EPS VS EstimatesTDOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30 -40 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
Also next year TDOC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TDOC Price Earnings VS Forward Price EarningsTDOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TDOC is valued cheaply inside the industry as 91.43% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than TDOC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 9.07
EV/EBITDA 9.43
TDOC Per share dataTDOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.58%
EPS Next 3Y11.86%

More info and screens

0

5. Dividend

5.1 Amount

TDOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELADOC HEALTH INC

NYSE:TDOC (9/3/2025, 7:29:25 PM)

After market: 7.7409 -0.02 (-0.25%)

7.76

+0.12 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners73.92%
Inst Owner Change-0.45%
Ins Owners0.59%
Ins Owner Change5.79%
Market Cap1.37B
Analysts67.88
Price Target9.21 (18.69%)
Short Float %13.51%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.76%
Min EPS beat(2)-54.19%
Max EPS beat(2)28.67%
EPS beat(4)2
Avg EPS beat(4)-1.86%
Min EPS beat(4)-54.19%
Max EPS beat(4)32.44%
EPS beat(8)5
Avg EPS beat(8)4.86%
EPS beat(12)8
Avg EPS beat(12)-761.2%
EPS beat(16)11
Avg EPS beat(16)-739.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.43%
Min Revenue beat(2)-0.51%
Max Revenue beat(2)-0.35%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.82%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.61%
Revenue beat(12)0
Avg Revenue beat(12)-1.47%
Revenue beat(16)0
Avg Revenue beat(16)-1.39%
PT rev (1m)0.72%
PT rev (3m)-2.01%
EPS NQ rev (1m)-7.5%
EPS NQ rev (3m)-22.1%
EPS NY rev (1m)0.55%
EPS NY rev (3m)-4.29%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-1.51%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)0.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF 9.07
P/OCF 4.52
P/B 0.96
P/tB N/A
EV/EBITDA 9.43
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)0.86
FCFY11.03%
OCF(TTM)1.72
OCFY22.13%
SpS14.39
BVpS8.05
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.17%
ROE -14.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.26%
FCFM 5.95%
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 6.57
Debt/EBITDA 5.63
Cap/Depr 42.28%
Cap/Sales 5.99%
Interest Coverage N/A
Cash Conversion 171.95%
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.58
Altman-Z -6.41
F-Score5
WACC7.61%
ROIC/WACCN/A
Cap/Depr(3y)48.66%
Cap/Depr(5y)42.76%
Cap/Sales(3y)6.01%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.14%
EPS Next Y8.25%
EPS Next 2Y16.58%
EPS Next 3Y11.86%
EPS Next 5Y6.7%
Revenue 1Y (TTM)-2.57%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-1.64%
Revenue Next Year-1.83%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.37%
Revenue Next 5Y2.58%
EBIT growth 1Y14.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year141.43%
EBIT Next 3Y35.4%
EBIT Next 5Y20.65%
FCF growth 1Y137.81%
FCF growth 3Y9.25%
FCF growth 5Y54.93%
OCF growth 1Y24.92%
OCF growth 3Y14.82%
OCF growth 5Y57.92%